TokenPost·
Moleculin Biotech Cuts Third-Quarter Net Loss 74% to $6.5 Million

$6.5M
quarterly net loss
Research and development expenses increased 20% to $4.5 million. The company had $7.3 million in cash and cash equivalents at Sept. 30, 2026.
Every crypto headline. One feed. Updated every minute.

Research and development expenses increased 20% to $4.5 million. The company had $7.3 million in cash and cash equivalents at Sept. 30, 2026.